MAZE (Maze Therapeutics) Buyback Yield %: -7.84 (As of Jul. 08, 2026)


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $32.18
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics Buyback Yield %?

Maze Therapeutics MAZE -2.01% 14 Buyback Yield % is -7.84 as of Jul. 08, 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 741 Biotechnology companies, Maze Therapeutics ranks better than 51.96% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Maze Therapeutics's current buyback yield was -7.84%.

Maze Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics Buyback Yield % Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 -13.22

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.49 -23.86 -21.67 -13.22 -9.60

MAZE vs AVBP, DMRA, CAPR: Buyback Yield % Comparison

For the Biotechnology subindustry, Maze Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maze Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Maze Therapeutics's Buyback Yield % falls into.


MAZE
14GF Score
Maze Therapeutics Inc MAZE
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Maze Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 270.275) / 2043.99048
=-13.22%

Maze Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 142.523) / 1484.6793
=-9.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -7.84 mean?
Maze Therapeutics (MAZE) has a Buyback Yield % of -7.84 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Maze Therapeutics and its competitors. According to the industry distribution chart, Maze Therapeutics ranks #356 out of 741 companies in the Biotechnology industry, placing it in the top 48%.
Is Maze Therapeutics' Buyback Yield % too high?
Maze Therapeutics' current Buyback Yield % is -7.84. Based on the distribution chart, Maze Therapeutics ranks #356 out of 741 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Buyback Yield % compare to AVBP and DMRA?
According to the Biotechnology industry distribution chart, Maze Therapeutics ranks #356 out of 741 companies for Buyback Yield %. This puts Maze Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Maze Therapeutics and its competitors. Maze Therapeutics's current Buyback Yield % is -7.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Buyback Yield % of -7.84. The current Buyback Yield % is -7.84. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Buyback Yield % is -7.84 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.18
Price